Navigation Links
Genomic Health Announces Multiple Colon Cancer Studies at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Date:1/21/2011

in a poster on Saturday, January 22.

Impact of Oncotype DX Test on Quality-Adjusted Life Expectancy and Costs in Patients with Stage II Colon Cancer

In an independent study led by authors Neal Meropol, University Hospital Seidman Cancer Center and Case Western Research University; Gary Lyman, Duke University; and Rebecca Chien and John Hornberger, Cedar Associates, results showed that clinical use of the Oncotype DX Recurrence Score to assess risk of recurrence in T3 stage II colon cancers with intact mismatch repair (MMR-P) is likely to improve quality-adjusted life expectancy and be cost-saving from a societal perspective.  Patient age and adverse effects associated with chemotherapy are important considerations in adjuvant treatment decisions. The study, "Use of a multigene prognostic assay for selection of adjuvant chemotherapy in patients with stage II colon cancer: Impact on quality-adjusted life expectancy and costs" (N. J. Meropol et al, Abstract #491), will be presented in a poster on Saturday, January 22.

"Our data support the notion that use of a genomic test like the Recurrence Score Assay may potentially reduce chemotherapy use, improve quality adjusted survival, and save health care costs," said Neal J. Meropol, M.D., Chief of the Division of Hematology and Oncology at University Hospitals Seidman Cancer Center and Case Western Reserve University.

Genomic Health and TGen Publish Laboratory Study Identifying Genes that May Impact Effectiveness of Oxaliplatin

Separately, Genomic Health and the Translational Genomics Research Institute published a laboratory study in Molecular Cancer Research that describes the identification of 27 genes that, when silenced, altered the sensitivity of colon tumor cells to the drug oxaliplatin.  Oxaliplatin is widely used in colon cancer; however a significant number of patients experience serious side effects.  This discove
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Everist Genomics Announces External Validation of OncoDefender™-CRC Test for Predicting Recurrence Risk for Stage I and II Colorectal Cancer Patients
2. BioInformatics, LLC New Market Report - Genomics Technologies
3. Transgenomic Reports Third Quarter Financial Results
4. Transgenomic Awarded $1,070,453 From U.S. Government Under the Patient Protection and Affordable Care Act
5. Transgenomic to Hold Third Quarter Financial Results Conference Call on November 15, 2010
6. Transgenomic Develops New Assays to Detect EGFR Mutations Using COLD-PCR
7. Sirius Genomics Announces Issuance of U.S. Patent
8. AutoGenomics Receives FDA Clearance for its INFINITI® CYP2C19 Assay
9. Genomic Health to Announce Third Quarter 2010 Financial Results and Host Conference Call on Monday, November 8, 2010
10. Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services
11. WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... May 20, 2015  Marc Tessier-Lavigne, president of ... of $100 million from The Marie-Josée and Henry ... laboratory building that will be the centerpiece of ... and Henry R. Kravis Research Building, two stories ... spanning approximately three city blocks following the shoreline ...
(Date:5/20/2015)... Bioscience announced today the successful results from their CLIA ... liquid biopsy for an ALK-gene fusion driver mutation found ... form of this cancer. Researchers or clinicians can now ... and direct them into clinical trials with a standard ... CLIA authority in Washington State , ...
(Date:5/20/2015)... Cambridge, MA (PRWEB) May 20, 2015 ... quality transporter assay services for Drug-Drug Interactions (DDI), ... Rhenovia Pharma, a world leader in assessing impact ... Quantitative Systems Pharmacology supported by biosimulation, announced today ... The agreement allows both companies to expand their ...
(Date:5/20/2015)... 20, 2015  OncoSec Medical Inc. ("OncoSec") (OTCQB: ... will present data from ongoing clinical and preclinical ... Emerging Approaches to Cancer Immunotherapy. OncoSec,s Chief Scientific ... Chief Medical Officer Mai. H. Le, MD, will ... IL-12 Can Increase CD8 TILs and Drive Systemic ...
Breaking Biology Technology:The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3OncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium 2OncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium 3OncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium 4
... 22, 2012 Bacterin International Holdings, Inc. (NYSE Amex: ... bone graft material and antimicrobial coatings for medical applications, today ... year ended December 31, 2011: Fourth Quarter ... million, compared to the $5.3 million for the fourth quarter ...
... The new Dynaflow Resolve System was ... to meet the demand for a simpler technology capable ... an advanced automated perfusion system that enables novel experimental ... using any cell type, and any compound. The new ...
... an inVentiv Health company and the leading management ... industry, today announced the launch of Encuity Research, ... a six-year veteran with Campbell Alliance, will serve ... be based in Newtown, PA. (Photo: ...
Cached Biology Technology:Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 2Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 3Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 4Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 5Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 6Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 7Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 8Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 9Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 10Cellectricon Launches Dynaflow® Resolve System Enabling Novel Ion Channel Assays 2Campbell Alliance Launches Market Research and Analytics Group, Appoints Michael Turner as General Manager of Encuity Research 2Campbell Alliance Launches Market Research and Analytics Group, Appoints Michael Turner as General Manager of Encuity Research 3Campbell Alliance Launches Market Research and Analytics Group, Appoints Michael Turner as General Manager of Encuity Research 4Campbell Alliance Launches Market Research and Analytics Group, Appoints Michael Turner as General Manager of Encuity Research 5
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/18/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... at the University of Georgia have discovered a central ... The misregulation of this switch may play a role ... the aggressiveness of tumors themselves. "Malignant cancer arises ... from their primary tissue location," said Natalia Starostina assistant ...
... BOSTON (December 7, 2010) Newly-created bioactive peptides promote ... and epithelial tissue, such as skin. These wound-healing peptides, ... in Wound Healing Research, increased angiogenesis in vitro by ... print this week in Wound Repair and Regeneration ...
... will meet again in So Paulo at the international ... to monitor new biodiversity conservation targets. The goal of ... for the conservation of biodiversity, as well as mechanisms ... event is organized by the Biota-FAPESP, the So Paulo ...
Cached Biology News:Study: mechanism that controls cell movement linked to tumors becoming more aggressive 2Study: mechanism that controls cell movement linked to tumors becoming more aggressive 3Bioactive peptides found to promote wound healing 2Bioactive peptides found to promote wound healing 3Biodiversity targets for the future 2Biodiversity targets for the future 3